



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Rua Bioscience Limited ( <b>Rua</b> )
Date this disclosure made:	17-Mar-22
Date of last disclosure:	8-Jun-21

**Director or senior manager giving disclosure**

Full name(s):	Manu Caddie
Name of listed issuer:	Rua Bioscience Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Kaihautu - Head of Innovation and Regulation of Rua

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:	Ordinary shares in Rua
Nature of the affected relevant interest(s):	Manu is a director and 50% shareholder of New Zealand Nutraceuticals Limited ( <b>NZNL</b> ). NZNL is the owner of 5,421,747 (before the transactions) and nil (after the transactions) ordinary shares in Rua.

**For that relevant interest-**

Number held in class before acquisition or disposal:	5,421,747
Number held in class after acquisition or disposal:	0
Current registered holder(s):	NZNL
Registered holder(s) once transfers are registered:	Manu Caddie and Damian Skinner

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	N/A
Class of underlying financial products:	N/A

**Details of affected derivative-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative(if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
<i>For that derivative,-</i>	N/A
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:	2
---	---

**Details of transactions requiring disclosure-**

Date of transaction:	17/03/2022
Nature of transaction:	Distribution in specie
Name of any other party or parties to the transaction (if known):	Manu Caddie and Damian Skinner
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	No cash consideration as the transactions are distributions in specie. The value of the shares being transferred is approximately \$2,449,003.11
Number of financial products to which the transaction related:	5,421,747
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	
Whether relevant interests were acquired or disposed of during a closed period:	Yes
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	Yes
Date of the prior written clearance (if any):	15/03/2022

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:	Ordinary shares in Rua
Nature of the affected relevant interest(s):	Manu is a director and 50% shareholder of NZNL. NZNL is distributing in specie 2,682,192 ordinary shares in Rua to Manu.
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	194,106
Number held in class after acquisition or disposal:	2,876,298
Current registered holder(s):	NZNL
Registered holder(s) once transfers are registered:	Manu Caddie

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	N/A
Class of underlying financial products:	N/A

**Details of affected derivative-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative(if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
<i>For that derivative,-</i>	N/A
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the	N/A

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:	1
---	---

**Details of transactions requiring disclosure-**

Date of transaction:	17/03/2022
Nature of transaction:	Distribution in specie
Name of any other party or parties to the transaction (if known):	NZNL
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	No cash consideration as the transaction is a distribution in specie. The value of the consideration is approximately \$1,211,546.12
Number of financial products to which the transaction relates:	2,682,192
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	

Whether relevant interests were acquired or disposed of during a closed period:	Yes
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	Yes
Date of the prior written clearance (if any):	15/03/2022


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	Ordinary shares in Rua
Nature of relevant interest:	Manu is a director and 50% shareholder of NZNL. NZNL is a limited partner of Hikurangi Bioactives Limited Partnership ( <b>HBLP</b> ) with a 40% economic interest in HBLP
<i>For that relevant interest,-</i>	
Number held in class:	1,600,000
Current registered holder(s):	HBLP

*For a derivative relevant interest,-*

Type of derivative:	N/A
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the	N/A
<i>For that derivative relevant interest,-</i>	N/A
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	